Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 20-May-24 8:11 PM View:  | Conway Robert Director | Nivalis Therapeutics, Inc. (ALPN) | 20-May-24 | Disposition | 50,000 | -- | -- | (100%) 50.0K to 0 | |
| 20-May-24 8:02 PM View: | Durand Remy Chief Business Officer | Nivalis Therapeutics, Inc. (ALPN) | 20-May-24 | Disposition | 133,392 | -- | -- | (100%) 133.39K to 0 | |
| 20-May-24 8:05 PM View: | Peng Stanford L See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 20-May-24 | Disposition | 344,163 | -- | -- | (100%) 344.16K to 0 | |
| 20-May-24 8:14 PM View: | Peetz Christopher Director | Nivalis Therapeutics, Inc. (ALPN) | 20-May-24 | Disposition | 1,900 | -- | -- | (100%) 1.9K to 0 | |
| 20-May-24 8:03 PM View: | Fuhs Ulrich Martin Chief Accounting Officer | Nivalis Therapeutics, Inc. (ALPN) | 20-May-24 | Disposition | 30,120 | -- | -- | (100%) 30.12K to 0 | |
| 20-May-24 8:04 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 20-May-24 | Disposition | 109,245 | -- | -- | (100%) 109.25K to 0 | |
| 20-May-24 8:07 PM View: | Rickey James Paul See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 20-May-24 | Disposition | 57,961 | -- | -- | (100%) 57.96K to 0 | |
| 20-May-24 8:04 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 18-May-24 | Disposition (change in control) | 2,627,160 | -- | -- | (96%) 2.74M to 109.25K | |
| 20-May-24 8:10 PM View: | Topper James N Director | Nivalis Therapeutics, Inc. (ALPN) | 18-May-24 | Disposition (change in control) | 2,829,350 | -- | -- | (100%) 2.83M to 0 | |
| 20-May-24 8:08 PM View: | Cui Xiangmin Director 10% Owner | Nivalis Therapeutics, Inc. (ALPN) | 18-May-24 | Disposition (change in control) | 8,317,920 | -- | -- | (100%) 8.32M to 0 | |
| 20-May-24 7:47 PM View: | Orbimed Advisors LLC Director | Nivalis Therapeutics, Inc. (ALPN) | 18-May-24 | Disposition (change in control) | 2,680,500 | -- | -- | (100%) 2.68M to 0 | |
| 20-May-24 8:09 PM View: | Thompson Peter A Director | Nivalis Therapeutics, Inc. (ALPN) | 18-May-24 | Disposition (change in control) Duplicate | 2,680,500 | -- | -- | (100%) 2.68M to 0 | |
| 10-May-24 7:22 PM View: | Fuhs Ulrich Martin Chief Accounting Officer | Nivalis Therapeutics, Inc. (ALPN) | 08-May-24 | Option Exercise | 22,820 | $12.07 | $275,437.00 | 313% 7.3K to 30.12K | |
| 10-May-24 7:24 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 08-May-24 | Option Exercise | 13,245 | $7.55 | $99,999.80 | < 1% 2.72M to 2.74M | |
| 10-May-24 7:25 PM View: | Durand Remy Chief Business Officer | Nivalis Therapeutics, Inc. (ALPN) | 08-May-24 | Option Exercise | 95,288 | $5.39 | $513,869.00 | 250% 38.1K to 133.39K | |
| 10-May-24 7:26 PM View: | Peng Stanford L See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 08-May-24 | Option Exercise | 271,792 | $2.46 | $669,403.00 | 376% 72.37K to 344.16K | |
| 09-May-24 9:13 PM View: | Rickey James Paul See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 07-May-24 | Option Exercise | 26,761 | $6.04 | $161,629.00 | 86% 31.2K to 57.96K | |
| 29-Apr-24 4:32 PM View: | Topper James N Director | Nivalis Therapeutics, Inc. (ALPN) | 25-Apr-24 | Exercise (in-the money or at-the-money) | 1,200,000 | $0.00 | $1,200.00 | 74% 1.63M to 2.83M | |
| 29-Apr-24 4:32 PM View: | Topper James N Director | Nivalis Therapeutics, Inc. (ALPN) | 25-Apr-24 | Sale | 19 | $64.57 | $1,226.83 | (< 1%) 2.83M to 2.83M | |
| 29-Jan-24 7:04 PM View: | Rickey James Paul See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 26-Jan-24 | Planned Option Sale | 117,764 | $23.32 | $2,745,830.00 | (100%) 117.76K to 0 | |
| 29-Jan-24 7:04 PM View: | Rickey James Paul See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 26-Jan-24 | Option Exercise | 117,764 | $8.30 | $977,844.00 | 100% 0 to 117.76K | |
| 29-Jan-24 7:04 PM View: | Rickey James Paul See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 25-Jan-24 | Planned Option Sale | 236 | $22.00 | $5,192.00 | (100%) 0.24K to 0 | |
| 29-Jan-24 7:04 PM View: | Rickey James Paul See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 25-Jan-24 | Option Exercise | 236 | $6.51 | $1,536.36 | 100% 0 to 0.24K | |
| 22-Jan-24 6:54 PM View: | Decheng Capital China Life ... 10% Owner | Nivalis Therapeutics, Inc. (ALPN) | 18-Jan-24 | Exercise (in-the money or at-the-money) | 1,234,640 | $12.74 | $15,729,300.00 | 23% 5.35M to 6.58M | |
| 22-Jan-24 5:48 PM View: | Cui Xiangmin Director 10% Owner | Nivalis Therapeutics, Inc. (ALPN) | 18-Jan-24 | Exercise (in-the money or at-the-money) Duplicate | 1,234,640 | $12.74 | $15,729,300.00 | 17% 7.08M to 8.32M | |
| 16-Jan-24 4:39 PM View: | Orbimed Advisors LLC Director | Nivalis Therapeutics, Inc. (ALPN) | 11-Jan-24 | Exercise (in-the money or at-the-money) Duplicate | 145,251 | $12.74 | $1,850,500.00 | 6% 2.54M to 2.68M | |
| 16-Jan-24 4:36 PM View: | Thompson Peter A Director | Nivalis Therapeutics, Inc. (ALPN) | 11-Jan-24 | Exercise (in-the money or at-the-money) | 145,251 | $12.74 | $1,850,500.00 | 6% 2.54M to 2.68M | |
| 05-Jan-24 6:08 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 04-Jan-24 | Grant | 96,000 | -- | -- | 4% 2.63M to 2.72M | |
| 05-Jan-24 6:07 PM View: | Rickey James Paul See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 04-Jan-24 | Grant | 31,200 | -- | -- | 100% 0 to 31.2K | |
| 05-Jan-24 6:06 PM View: | Durand Remy Chief Business Officer | Nivalis Therapeutics, Inc. (ALPN) | 04-Jan-24 | Grant | 31,200 | -- | -- | 452% 6.9K to 38.1K | |
| 05-Jan-24 6:08 PM View: | Peng Stanford L See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 04-Jan-24 | Grant | 48,000 | -- | -- | 197% 24.37K to 72.37K | |
| 29-Dec-23 4:18 PM View: | Orbimed Advisors LLC Director | Nivalis Therapeutics, Inc. (ALPN) | 28-Dec-23 | Sale | 1,364,850 | $18.35 | $25,049,000.00 | (35%) 3.9M to 2.54M | |
| 29-Dec-23 4:20 PM View: | Thompson Peter A Director | Nivalis Therapeutics, Inc. (ALPN) | 28-Dec-23 | Sale Duplicate | 1,364,850 | $18.35 | $25,049,000.00 | (35%) 3.9M to 2.54M | |
| 29-Dec-23 7:32 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 28-Dec-23 | Planned Option Sale | 1,016 | $20.04 | $20,362.00 | (< 1%) 2.63M to 2.63M | |
| 29-Dec-23 7:32 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 28-Dec-23 | Payment of Exercise | 48,264 | $19.65 | $948,388.00 | (2%) 2.68M to 2.63M | |
| 29-Dec-23 7:32 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 28-Dec-23 | Option Exercise | 74,441 | $12.74 | $948,378.00 | 3% 2.6M to 2.68M | |
| 29-Dec-23 7:32 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 28-Dec-23 | Option Exercise | 1,016 | $0.65 | $660.40 | < 1% 2.68M to 2.68M | |
| 27-Dec-23 9:07 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 27-Dec-23 | Planned Option Sale | 29,573 | $20.04 | $592,717.00 | (1%) 2.63M to 2.6M | |
| 27-Dec-23 9:07 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 27-Dec-23 | Option Exercise | 29,573 | $0.65 | $19,222.40 | 1% 2.6M to 2.63M | |
| 29-Dec-23 4:18 PM View: | Orbimed Advisors LLC Director | Nivalis Therapeutics, Inc. (ALPN) | 27-Dec-23 | Private Sale | 181,498 | $19.96 | $3,622,700.00 | (4%) 4.08M to 3.9M | |
| 29-Dec-23 4:20 PM View: | Thompson Peter A Director | Nivalis Therapeutics, Inc. (ALPN) | 27-Dec-23 | Private Sale Duplicate | 181,498 | $19.96 | $3,622,700.00 | (4%) 4.08M to 3.9M | |
| 27-Dec-23 9:07 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 26-Dec-23 | Planned Option Sale | 24,486 | $20.22 | $495,217.00 | (< 1%) 2.63M to 2.6M | |
| 27-Dec-23 9:07 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 26-Dec-23 | Option Exercise | 24,486 | $0.63 | $15,435.50 | < 1% 2.6M to 2.63M | |
| 27-Dec-23 9:07 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 22-Dec-23 | Planned Option Sale | 37,825 | $20.43 | $772,595.00 | (1%) 2.64M to 2.6M | |
| 27-Dec-23 9:07 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 22-Dec-23 | Option Exercise | 37,825 | $0.45 | $17,021.20 | 1% 2.6M to 2.64M | |
| 21-Dec-23 7:34 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 19-Dec-23 | Planned Option Sale | 2,402 | $20.01 | $48,063.80 | (< 1%) 2.6M to 2.6M | |
| 21-Dec-23 7:35 PM View: | Rickey James Paul See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 19-Dec-23 | Option Exercise | 15,213 | $5.02 | $76,369.30 | 100% 0 to 15.21K | |
| 21-Dec-23 7:34 PM View: | Gold Mitchell Executive Chairman and CEO Director | Nivalis Therapeutics, Inc. (ALPN) | 19-Dec-23 | Option Exercise | 2,402 | $0.45 | $1,080.90 | < 1% 2.6M to 2.6M | |
| 21-Dec-23 7:35 PM View: | Rickey James Paul See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 19-Dec-23 | Planned Option Sale | 15,213 | $19.21 | $292,222.00 | (100%) 15.21K to 0 | |
| 18-Dec-23 9:20 PM View: | Rickey James Paul See Remarks | Nivalis Therapeutics, Inc. (ALPN) | 18-Dec-23 | Planned Option Sale | 1,800 | $19.00 | $34,203.10 | (100%) 1.8K to 0 |
